Scinai regains Nasdaq $1 minimum bid compliance

Scinai Immunotherapeutics Ltd. (SCNI) reports that it has regained compliance with Nasdaq’s $1.00 minimum bid price requirement under Listing Rule 5550(a)(2).

Available on EDGAR 09/21/2026 - 07:00 AM EDT Accepted by SEC EDGAR 09/21/2026 - 07:00 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Scinai Immunotherapeutics Ltd. (SCNI) reports that it has regained compliance with Nasdaq’s $1.00 minimum bid price requirement under Listing Rule 5550(a)(2). Nasdaq notified the company that, for 19 consecutive business days from August 21, 2026 through September 17, 2026, the closing bid price of Scinai’s American Depositary Shares was at or above $1.00, and the prior deficiency matter is now closed.

The company states that, with this listing issue resolved, it remains focused on commercial execution at its Scinai Biopharma Services CDMO business and on advancing its NanoAb immunology therapy programs developed under collaborations with the Max Planck Society and University Medical Center Göttingen.

Positive

• Nasdaq confirmed Scinai has regained compliance with the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2), and stated that the listing deficiency matter is closed.

Negative

• None.

Filing Explained

Separately from the Nasdaq update, Scinai states that this 6-K, excluding its third paragraph, is incorporated by reference into its listed S-8 and F-3 registration statements; this filing action does not disclose a new issuance or sale.

Key Figures

Minimum bid price threshold: $1.00 per ADS Consecutive days at or above threshold: 19 business days Deficiency measurement window: 30 business days +2 more

5 metrics

Minimum bid price threshold $1.00 per ADS Nasdaq Listing Rule 5550(a)(2) minimum bid price requirement

Consecutive days at or above threshold 19 business days Closing bid price at or above $1.00 from August 21, 2026 through September 17, 2026

Deficiency measurement window 30 business days Period over which ADSs previously failed to maintain $1.00 minimum bid price as of March 12, 2026 notice

Compliance confirmation date September 18, 2026 Date of Nasdaq’s written notification that Scinai had regained compliance

Press release date September 21, 2026 Date Scinai announced it had regained compliance with Nasdaq’s minimum bid price rule

Key Terms

Nasdaq Listing Rule 5550(a)(2), American Depositary Shares, contract development and manufacturing organization, forward-looking statements, +1 more

5 terms

Nasdaq Listing Rule 5550(a)(2) regulatory

"compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2)"

American Depositary Shares financial

"the Company’s American Depositary Shares (“ADSs”) had failed to maintain a minimum bid price"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

contract development and manufacturing organization technical

"a revenue-generating contract development and manufacturing organization (“CDMO”)"

A contract development and manufacturing organization (CDMO) is a specialized service provider that helps other companies design, test, produce and package drugs or medical products on a hired basis. Think of it as an outsourced factory and R&D partner that lets a company scale production without building its own plants. Investors watch CDMO relationships because they affect a drug’s time-to-market, manufacturing costs, supply reliability and overall project risk, all of which influence future revenue and valuation.

forward-looking statements regulatory

"This press release contains forward-looking statements within the meaning of the U.S. Private Securities"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Registration Statements on Form F-3 regulatory

"incorporated by reference into the registrant’s Registration Statements on Form S-8 and Form F-3"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Scinai Immunotherapeutics (SCNI) announce in its September 2026 Form 6-K?

Scinai announced it received Nasdaq notification that it has regained compliance with the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2), and that the prior minimum bid price deficiency matter is now closed.

How did SCNI regain compliance with Nasdaq’s minimum bid price rule?

Nasdaq’s September 18, 2026 letter stated that, for 19 consecutive business days from August 21, 2026 through September 17, 2026, Scinai’s ADS closing bid price was $1.00 per share or greater, restoring compliance with Listing Rule 5550(a)(2).

What Nasdaq rule is relevant to Scinai Immunotherapeutics’ listing status?

Scinai’s listing status relates to Nasdaq Listing Rule 5550(a)(2), which requires a $1.00 minimum bid price for securities listed on the Nasdaq Capital Market. Nasdaq confirmed Scinai is again in compliance with this rule.

When was Scinai Immunotherapeutics (SCNI) first notified of its bid price deficiency?

On March 12, 2026, Nasdaq Staff notified Scinai that its American Depositary Shares had failed to maintain a minimum bid price of $1.00 over the prior 30 consecutive business days, triggering a minimum bid price deficiency notice.

What strategic focus did SCNI highlight after resolving the Nasdaq compliance matter?

Scinai’s CEO stated that, with the compliance matter resolved, the company’s focus remains on commercial execution at Scinai Biopharma Services, its CDMO business, and on the disciplined advancement of its NanoAb programs in innovative immunology therapies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of September 2026

Commission File Number: 001-37353

SCINAI IMMUNOTHERAPEUTICS LTD.

(Translation of registrant’s name into English)

Jerusalem BioPark, 2nd Floor

Hadassah Ein Kerem Campus

Jerusalem, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

Explanatory Note

On September 21, 2026, Scinai Immunotherapeutics Ltd. issued a press release titled “Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement.”

A copy of the press release is furnished herewith as Exhibit 99.1.

This Report on Form 6-K (other than the third paragraph thereof) is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File Nos. 333-291460, 333-271293 and 333-239344) and Form F-3 (File Nos. 333-295698 and 333-276767), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished..

1

Exhibit Index

Exhibit No.		Description
99.1		Press release dated September 21, 2026.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Scinai Immunotherapeutics Ltd.
Date: September 21, 2026	By:	/s/ Amir Reichman
		Amir Reichman
		Chief Executive Officer

3

Exhibit 99.1

Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement

Nasdaq confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above $1.00; minimum bid price matter is closed

JERUSALEM, September 21, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (“Scinai” or the “Company”), a biopharmaceutical company combining innovative immunology therapeutic development with a revenue-generating contract development and manufacturing organization (“CDMO”), today announced that it has received written notification from Nasdaq Listing Qualifications confirming that the Company has regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and that the matter is now closed.

On March 12, 2026, Nasdaq Staff notified Scinai that the Company’s American Depositary Shares (“ADSs”) had failed to maintain a minimum bid price of $1.00 over the prior 30 consecutive business days. In its September 18, 2026 compliance letter, Nasdaq stated that for the 19 consecutive business days from August 21, 2026 through September 17, 2026, the closing bid price of Scinai’s ADSs was at $1.00 per share or greater. Accordingly, Nasdaq determined that Scinai had regained compliance with Listing Rule 5550(a)(2).

“Receiving Nasdaq’s confirmation closes an important compliance matter for Scinai,” said Amir Reichman, Chief Executive Officer of Scinai. “We appreciate Nasdaq Staff’s review and constructive engagement throughout the process. With this matter resolved, our focus remains on commercial execution at Scinai Biopharma Services and disciplined advancement of our NanoAb programs.”

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on the development of innovative immunology therapies and the operation of a contract development and manufacturing organization. The Company is developing its NanoAb platform through research collaboration and license arrangements with the Max Planck Society and University Medical Center Göttingen.

Scinai also owns Scinai Biopharma Services Ltd., a CDMO providing development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel.

For more information, please visit www.scinai.com.

Company Contacts

Business Development | +972 8 930 2529 | bd@scinai.com

Investor Relations, Allele Capital Partners | +1 (561) 388-8178| BDeBeer@allelecapital.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws. These include statements regarding the Company’s continued commercial execution, CDMO growth and customer programs, NanoAb development and the Company’s ability to maintain compliance with Nasdaq listing requirements.

These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Such risks include the Company’s ability to secure sufficient financing or non-dilutive funding on satisfactory terms or at all; increase CDMO revenues and execute customer programs; maintain research and license arrangements; generate supportive preclinical or clinical data; obtain regulatory approvals; secure development partners; maintain compliance with Nasdaq listing requirements; and respond to competition and market, regulatory, geopolitical and economic conditions. Additional information appears in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F filed on April 1, 2026. Forward-looking statements speak only as of the date of this press release. Except as required by law, the Company undertakes no obligation to update or revise them.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE DATED SEPTEMBER 21, 2026 9.4 KB